Drug intelligence / Profile preview

TQ-B3234

Development stage: Unknown
Lead developer: Sino Biopharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

TQ-B3234 is an orally bioavailable small molecule inhibitor of MEK1 and MEK2. It is being developed by Sino Biopharmaceutical (Chia Tai Tianqing) and Shouyao Holdings for the treatment of neurofibromatosis type 1 (NF1) related plexiform neurofibromas. The drug targets the MAPK/ERK signaling pathway, which is often hyperactivated in NF1 due to the loss of neurofibromin, a negative regulator of Ras. By inhibiting MEK, TQ-B3234 prevents the downstream activation of ERK, thereby inhibiting tumor cell proliferation and survival. It is currently being evaluated in Phase III clinical trials for patients with symptomatic, inoperable plexiform neurofibromas.

Targets

MEK1 (Dual specificity mitogen-activated protein kinase kinase 1)MEK2 (Dual specificity mitogen-activated protein kinase kinase 2)

Beyond the preview

Go deeper on TQ-B3234.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TQ-B3234.

Explore the full profile